glycoside 3c

Glycoside 3c is an experimental small molecule N-acetylglucosamine (NAG) derivative of a phenolic compound, developed as a potential therapeutic agent for Type 2 diabetes mellitus (T2DM). It belongs to a novel class of marine-derived $\alpha$-glucosidase inhibitors synthesized by modifying common phenolic scaffolds with NAG, a monosaccharide derived from chitin. The drug is designed to inhibit the activity of $\alpha$-glucosidase, an enzyme responsible for breaking down complex carbohydrates into glucose in the digestive tract. By slowing this process, glycoside 3c aims to reduce postprandial blood glucose levels. While its analog, glycoside 3a, was identified as the most potent in the series, glycoside 3c was evaluated for its enhanced binding affinity and inhibitory potential compared to its parent phenolic compound.

Other names

N-acetylglucosamine glycoside 3c